Details of the Drug
General Information of Drug (ID: DMQFSI5)
| Drug Name |
Retagliptin
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
DPP4 inhibitors, Shanghai Hengrui Pharmaceutical Co Ltd; SHR-1039; SHR-1040; DPPIV inhibitors (diabetes), Shanghai Hengrui Pharmaceutical Co Ltd; Dipeptidyl peptidase IV inhibitors (diabetes), Shanghai Hengrui Pharmaceutical Co Ltd
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 464.4 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.5 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 6 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 11 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Non-insulin dependent diabetes | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 5A11 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


